Steadfast Capital Management LP decreased its holdings in shares of Humana Inc. (NYSE:HUM) by 47.5% in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 634,261 shares of the insurance provider’s stock after selling 574,171 shares during the period. Humana makes up 2.8% of Steadfast Capital Management LP’s holdings, making the stock its 13th largest position. Steadfast Capital Management LP owned 0.44% of Humana worth $152,616,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Prisma Capital Partners LP bought a new stake in shares of Humana during the 2nd quarter valued at $7,122,000. Teachers Advisors LLC raised its position in shares of Humana by 31.6% during the 2nd quarter. Teachers Advisors LLC now owns 630,835 shares of the insurance provider’s stock valued at $151,792,000 after acquiring an additional 151,603 shares during the last quarter. Federated Investors Inc. PA raised its position in shares of Humana by 608.1% during the 2nd quarter. Federated Investors Inc. PA now owns 34,626 shares of the insurance provider’s stock valued at $8,331,000 after acquiring an additional 29,736 shares during the last quarter. Commonwealth Bank of Australia raised its position in shares of Humana by 4.0% during the 2nd quarter. Commonwealth Bank of Australia now owns 20,316 shares of the insurance provider’s stock valued at $4,887,000 after acquiring an additional 775 shares during the last quarter. Finally, Cipher Capital LP raised its position in shares of Humana by 7.7% during the 2nd quarter. Cipher Capital LP now owns 9,734 shares of the insurance provider’s stock valued at $2,342,000 after acquiring an additional 698 shares during the last quarter. Institutional investors own 95.12% of the company’s stock.

Shares of Humana Inc. (NYSE HUM) traded up 0.95% during midday trading on Friday, hitting $247.69. 348,711 shares of the stock were exchanged. The stock has a market capitalization of $35.80 billion, a price-to-earnings ratio of 20.38 and a beta of 0.86. Humana Inc. has a 1-year low of $163.50 and a 1-year high of $259.76. The firm’s 50 day moving average is $249.11 and its 200-day moving average is $234.09.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, August 2nd. The insurance provider reported $3.49 EPS for the quarter, topping the consensus estimate of $3.08 by $0.41. Humana had a net margin of 3.37% and a return on equity of 15.85%. The business had revenue of $13.53 billion for the quarter, compared to analyst estimates of $13.61 billion. During the same quarter in the previous year, the firm posted $2.30 earnings per share. On average, analysts predict that Humana Inc. will post $11.55 EPS for the current year.

The firm also recently declared a dividend, which will be paid on Monday, October 16th. Stockholders of record on Friday, September 29th will be given a $0.40 dividend. The ex-dividend date is Thursday, September 28th. Humana’s dividend payout ratio (DPR) is currently 13.06%.

Several brokerages have recently issued reports on HUM. BidaskClub raised shares of Humana from a “sell” rating to a “hold” rating in a report on Wednesday, August 23rd. ValuEngine raised shares of Humana from a “hold” rating to a “buy” rating in a report on Friday, September 1st. Argus raised shares of Humana from a “hold” rating to a “buy” rating and set a $260.00 price target for the company in a report on Friday, June 9th. Morgan Stanley boosted their price target on shares of Humana from $269.00 to $276.00 and gave the company an “overweight” rating in a report on Thursday, August 17th. Finally, Cowen and Company reissued an “outperform” rating and issued a $275.00 price target (up previously from $230.00) on shares of Humana in a report on Wednesday, September 20th. Nine equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The company has an average rating of “Buy” and an average target price of $247.50.

In other news, insider William Kevin Fleming sold 3,071 shares of the business’s stock in a transaction that occurred on Wednesday, August 23rd. The shares were sold at an average price of $250.98, for a total value of $770,759.58. Following the sale, the insider now owns 7,681 shares of the company’s stock, valued at $1,927,777.38. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Bruce D. Broussard sold 12,000 shares of the business’s stock in a transaction that occurred on Friday, August 11th. The shares were sold at an average price of $251.88, for a total transaction of $3,022,560.00. Following the completion of the sale, the chief executive officer now directly owns 80,086 shares in the company, valued at approximately $20,172,061.68. The disclosure for this sale can be found here. In the last three months, insiders sold 55,595 shares of company stock worth $14,133,706. Insiders own 0.80% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/10/06/steadfast-capital-management-lp-sells-574171-shares-of-humana-inc-hum.html.

About Humana

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Stock Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related stocks with our FREE daily email newsletter.